25

Might per chance

2023

|

13:59 PM

Europe/Amsterdam

No longer supposed for U.S. and UK Media

Summary

Bayer continues to apartment advancing prostate cancer care from early to metastatic stage with darolutamide knowledge in non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), and radium-223 dichloride knowledge in metastatic castration-resistant prostate cancer (mCRPC) / Confirming Bayer’s investment in Precision Oncology, larotrectinib knowledge offered at ASCO display lengthy-term efficacy and security in sufferers with tropomyosin receptor kinase (TRK) fusion lung and thyroid cancer, as successfully as to knowledge from investigator-initiated analysis in pediatric sufferers with newly identified childish fibrosarcoma (IFS)